- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:34 | Zyversa Therapeutics Inc expected to post a loss of $3.70 a share - Earnings Preview | 1 | Reuters | ||
| 29.04. | What's Going On With ZyVersa Stock? | 2 | Benzinga.com | ||
| 29.04. | ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease | 1 | GlobeNewswire (USA) | ||
| 25.04. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 17.04. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.04. | ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes | 110 | GlobeNewswire (Europe) | Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide.The published data... ► Artikel lesen | |
| 25.03. | ZyVersa Therapeutics GAAP EPS of -$0.29 | 3 | Seeking Alpha | ||
| 25.03. | ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update | 166 | GlobeNewswire (Europe) | Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical program... ► Artikel lesen | |
| 25.03. | ZyVersa Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 18.03. | ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease | 101 | GlobeNewswire (Europe) | Phase 2a trial is on track to begin in the first half of 2024.Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system... ► Artikel lesen | |
| 14.03. | ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled "Inflammation Illuminated,"at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024 | 2 | GlobeNewswire (USA) | ||
| 08.03. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.03. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 29.02. | ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity | 156 | GlobeNewswire (Europe) | ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including NLRP3, and their associated ASC specks to attenuate initiation... ► Artikel lesen | |
| 28.02. | ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications | 138 | GlobeNewswire (Europe) | Obesity, which affects over 1.9 billion people worldwide, is a state of low-grade chronic inflammation that causes an array of different metabolic disorders, including insulin resistance, type 2 Diabetes... ► Artikel lesen | |
| 26.02. | Microcap ZyVersa up 71% on study supporting new way to fight obesity | 7 | Seeking Alpha | ||
| 26.02. | What In The World Is Going On With ZyVersa Therapeutics (ZVSA) Stock? | 7 | Benzinga.com | ||
| 26.02. | Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today? | 7 | InvestorPlace | ||
| 22.02. | ZyVersa reports progress on neurological inflammation drug | 3 | Investing.com | ||
| 22.02. | ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option | 1 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,870 | +1,30 % | Qiagen zuletzt sehr stark. Der Montag wird wahnsinnig wichtig! | Grund zum Feiern haben heute alle Qiagen-Aktionäre. Schließlich errechnet sich im Vergleich zur Vorwoche ein Zugewinn von 2,87 Prozent. Das Wertpapier verabschiedete sich an vier der vier Sitzungen... ► Artikel lesen | |
| NOVAVAX | 8,249 | +96,47 % | Novavax Aktie: Aktionäre zu Revolte aufgerufen | Ein bedeutender Anteilseigner eines Biotechnologieunternehmens hat öffentlich Änderungen im Vorstand und Management gefordert, um die sinkende Leistung der Firma umzukehren. Kritik gab es insbesondere... ► Artikel lesen | |
| EVOTEC | 9,520 | -1,30 % | Evotec Aktie an wichtiger Kursmarke: Kommen Shortseller unter Druck? | Zum letzten Handelstag der Woche ein Blick auf die Evotec Aktie, die mit ihren Erholungsversuchen nach dem Absturz auf 8,52 Euro nicht wirklich vom Fleck kommt. In den vergangenen Tagen konnte nur ein... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,920 | +28,72 % | ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results | ||
| ITEOS THERAPEUTICS | 17,240 | +41,43 % | iTeos Therapeutics Inc.: iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates | - Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor reduction... ► Artikel lesen | |
| JANUX THERAPEUTICS | 49,640 | -4,43 % | Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| MORPHOSYS | 67,00 | 0,00 % | EQS-PVR: MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: MorphoSys AG
MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
03.05.2024 / 16:00 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,610 | -0,35 % | Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews | ||
| BIONTECH | 86,20 | -0,46 % | BioNTech Aktie: Unerwarteter Aufwärtstrend | Trotz des Fehlens offenkundiger Gründe für einen Anstieg verzeichnet die Aktie des Biotechnologieunternehmens BioNTech ein leichtes Plus von 0,23% auf 86,2 € im Vergleich zur Vorwoche. Dies geschieht... ► Artikel lesen | |
| ARCELLX | 50,42 | -4,38 % | Arcellx Provides First Quarter 2024 Financial Results | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 7,790 | +4,01 % | Sana Biotechnology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| AVIDITY BIOSCIENCES | 26,150 | -3,61 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights | Initiation of global Phase 3 HARBOR trial for del-desiran (AOC 1001) in DM1 on track for this quarter
Avidity to report FSHD data from FORTITUDE trial this quarter and DMD data from EXPLORE44 trial... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,015 | -0,19 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in... ► Artikel lesen | |
| IMMUNOVANT | 29,720 | +0,07 % | Pre-market Movers: Kaival Brands, Lufax Holding, Tourmaline Bio, Laser Photonics Corporation, Immunovant | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Kaival Brands Innovations Group... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,390 | -2,22 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera's Board of Directors granted inducement... ► Artikel lesen |
Das Unternehmen ZYVERSA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,65 % bei einem Aktienkurs von 5,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
